D. Walker

发表

Property-based design: optimization of drug absorption and pharmacokinetics.

H. van de Waterbeemd, D. Smith, K. Beaumont, 2001, Journal of medicinal chemistry.

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

N. Wood, D. Smith, D. Walker, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.

D. Smith, D. Walker, D. Stopher, 1992, Xenobiotica; the fate of foreign compounds in biological systems.

PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals

P. Taupin, D. Walker, B. K. Park, 2009 .

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog

D. Walker, D. Leishman, A. Harrison, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK

Han van de Waterbeemd, H. Waterbeemd, D. Walker, 2006 .

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT).

D. Walker, M. Potchoiba, C. Schroeder, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man

D. Walker, S. Roffey, S. Cole, 2003, Xenobiotica; the fate of foreign compounds in biological systems.

Metabolite Testing in Drug Development

D. Walker, A. Nedderman, D. Walker, 2011 .

Human Genotoxic Metabolites: Identification and Risk Management

D. Walker, A. Teasdale, K. Dobo, 2011 .

Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver.

G. Tucker, D. Smith, D. Walker, 1995, Xenobiotica; the fate of foreign compounds in biological systems.

SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.

D. Walker, M. Trevethick, E. Stuart, 2009, Bioorganic & medicinal chemistry letters.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

D. Walker, Dennis A. Smith, B. Jones, 1996, Medicinal research reviews.

Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.

Peter G. Dodd, D. Walker, M. Trevethick, 2008, Bioorganic & medicinal chemistry letters.

Evaluation of the role of the asialoglycoprotein receptor in the clearance of UK-279,276 (recombinant neutrophil inhibitory factor)

D. Walker, R. Hyland, R. Webster, 2003, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and clearance processes of UK-279,276 (rNIF) in rat and dog: Comparison with human data

D. Walker, R. Webster, A. Edgington, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

D A Smith, D K Walker, D. Walker, 1996, Medicinal research reviews.

Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man

D. A. Smith, D. Smith, K. Beaumont, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.

D. Walker, G. Muirhead, P. Wastall, 2002, British journal of clinical pharmacology.

Metabolic (Hepatic) Clearance

H. Waterbeemd, D. Walker, Dennis A. Smith, 2001 .

Bioanalytical data in decision making: discovery and development.

D A Smith, K Beaumont, N J Cussans, 1992, Xenobiotica; the fate of foreign compounds in biological systems.

The application of fully automated on-line solid phase extraction in bioanalysis.

D. Walker, Rachelle Christian, R. J. Mitchell, 2010, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs.

D. Walker, T. Rowan, A. D. Jernigan, 2002, Journal of veterinary pharmacology and therapeutics.

Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate.

D. Walker, M. Longo, Jon Rhodes, 2018, Birth defects research.

Applications of High‐Sensitivity Mass Spectrometry and Radioactivity Detection Techniques in Drug Metabolism Studies

D. Walker, C. Loi, A. Nedderman, 2008 .

A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

Don Walker, Joe Brady, Deepak Dalvie, 2009, Chemical research in toxicology.

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

D. Walker, M. Potchoiba, C. Schroeder, 2008 .

Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations

D. Walker, I. Gardner, J. Davis, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and Metabolism in Drug Design: Smith: Pharmacokinetics

H. Waterbeemd, D. Walker, Dennis A. Smith, 2001 .

Pharmacokinetics in Man

D. Walker, D. Nichols, 2009 .

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.

Angus N R Nedderman, Samantha Abel, D. Walker, 2008, British journal of clinical pharmacology.

Pharmacokinetics and metabolism in drug design

Han van de Waterbeemd, H. Waterbeemd, D. Walker, 2001 .

Pharmacokinetics and Metabolism in Drug Design: SMITH:PHARMACOKINETICS 3E O-BK

H. Waterbeemd, A. Kalgutkar, D. Walker, 2012 .

In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.

Michael B Bolger, D. Walker, M. Bolger, 2012, Molecular pharmaceutics.

SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV

Samantha Abel, D. Walker, Dennis A. Smith, 2005, Drug Metabolism and Disposition.

The use of C(av) rather than AUC in safety assessment.

D A Smith, D K Walker, D. Smith, 2010, Regulatory toxicology and pharmacology : RTP.

Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics

Han van de Waterbeemd, H. Waterbeemd, K. Beaumont, 2001 .

PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.

D. Walker, R. Xie, R. Webster, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

The use of 96-well Scintiplates to facilitate definitive metabolism studies for drug candidates.

D. Walker, A. Nedderman, M. Savage, 2004, Journal of pharmaceutical and biomedical analysis.